RxDoctor Payments Data

Brittany Labit-Hernandez

Nurse Practitioner · Yuma, AZNPI 1255075156

Payments from drug & device makers

$1,669in general payments, 2019–2025

Across 64 payments — averaging $26.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$254
  • AstraZeneca$226
  • OPKO Pharmaceuticals, LLC$181
  • Akebia Therapeutics Inc$175
  • Ardelyx, Inc.$174
  • Medtronic$140
  • plus $518 from 9 others

What the payments were for

  • Food & beverage$1,669100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,669 in reported general payments places this provider in the 85th percentile of 1,719 nurse practitioner providers in Arizona.

See all nurse practitioner providers in Arizona

Medicare billing

Part B allowed, 2024
$38,975
Medicare patients
307
Services billed
450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide22$124,660
LokelmaSodium Zirconium Cyclosilicate106$100,170
FarxigaDapagliflozin Propanediol27$29,340
JardianceEmpagliflozin14$15,365
Sevelamer Carbonate30$7,519
Calcium Acetate40$3,917
Calcitriol134$2,733
Midodrine Hcl41$2,061
Bumetanide39$1,739
Nifedipine ErNifedipine48$1,641
Losartan Potassium77$1,035
Isosorbide Mononitrate ErIsosorbide Mononitrate58$921
Amlodipine Besylate91$865
Furosemide91$596
Hydralazine Hcl37$590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$226$129,510133 claims
Fresenius USA Marketing, Inc.Velphoro$95$124,66022 claims
Boehringer IngelheimJardiance$15$15,36514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,719 nurse practitioner providers in Arizona.

Other nurse practitioner in Yuma

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →